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S U M M A R Y
Objectives: To assess the epidemiological pattern of Candida bloodstream infection (BSI) over an 8-year
period (2002–2009) in King Abdulaziz Medical City, western Saudi Arabia.
Method: A retrospective chart review was performed.
Results: A total of 258 BSI were identiﬁed in 134 males (53.2%) and 118 females (46.8%). There were 86
(34.1%) cases of Candida albicans and 166 (65.9%) non-albicans Candida species. Malignancy was
independently associated with the development of candidemia by non-albicans Candida species (odds
ratio 3.24, 95% conﬁdence interval 1.25–8.41). Fluconazole in vitro susceptibility was 38.5% for C.
albicans and 52.5% for other Candida species. The overall, crude 12-month mortality rate was 50% for C.
albicans and 57.8% for non-albicans Candida species.
Conclusions: The antifungal resistance coinciding with a change in the epidemiologic pattern of
candidemia identiﬁed in this study is alarming and urges the need for a review of empiric antifungal
therapy and potential contributing environmental factors.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Candidemia is associated with signiﬁcant morbidity and
mortality, especially if initial antifungal therapy is delayed or is
not appropriate.1–3 Mortality attributable to candidemia is
approximately 86% among intensive care unit (ICU) patients and
42% among non-ICU patients.4–6 Candidemia has been reported as
the fourth most common type of hospital-acquired bloodstream
infection (BSI) in the USA, with a higher prevalence among
immune-compromised patients, where candidemia represents
11% of all BSI.3 The incidence of candidemia in US hospitals during
2000–2005 increased from 3.65 to 5.56 episodes per 100 000* Corresponding author. Tel.: +966 2 6240000 ext. 22138;
fax: +966 2 6240000 ext. 22140.
E-mail address: thaqaﬁao1@ngha.med.sa (A.O. Al Thaqaﬁ).
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http://dx.doi.org/10.1016/j.ijid.2013.12.012population.7 Incidences are usually 10-fold higher in the ICUs
compared to other hospital wards (i.e., 3–15 episodes per 10 000
ICU patient-days).8 Data from Europe have shown that the
incidence of candidemia may be lower, with proportions ranging
from 2% to 3% of bloodstream isolates.9 Furthermore, studies in the
late 1990s reported that there had been an important shift in the
types of Candida infection away from Candida albicans to more
treatment-resistant, non-albicans Candida species.10
Many risk factors associated with the development of invasive
candidiasis have been identiﬁed, including receiving broad-spec-
trum antibiotics, chemotherapy, or steroids, the presence of a central
venous catheter (CVC), the administration of total parenteral
nutrition (TPN), complicated abdominal surgery, malignancy,
neutropenia, and acute renal failure (ARF).11 Assessing these risk
factors and developing a valid risk score is important for early
intervention with the appropriate antifungal therapy, and hence
reducing the burden of infection.
In Saudi Arabia, variable numbers of episodes of candidemia in
hospitals have been reported, ranging from 3 to 42 episodes
per year; these studies have used different study designsociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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Figure 1. Distribution of Candida albicans and non-albicans species from 2002 to
2009.
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ICU).12–17 Meanwhile, it was noticed that the total number of
candidemia cases in King Abdulaziz Medical City (KAMC) in
western Saudi Arabia during an 8-year period from 2002 to 2009,
was relatively higher than previously reported data from other
regions of Saudi Arabia. Therefore, the current study was
conducted to investigate and describe the epidemiological
characteristics over these years and to identify predictors of the
outcomes of the different types of Candida BSI at this tertiary care
hospital in Saudi Arabia.
2. Methods
This was a retrospective analysis of prospectively collected data
on all patients admitted to KAMC and found to have positive blood
cultures for Candida species during the period January 2002 to
December 2009. KAMC is a 500-bed tertiary care teaching hospital
with nine satellite primary healthcare centers that serve all
National Guard military personnel and their dependents (spouses,
children, and parents) in the western region of Saudi Arabia.
Patients were identiﬁed and included in a speciﬁcally designed
database upon identiﬁcation of a positive blood culture for Candida
species, as reported by the clinical microbiology department. This
database comprises demographic and clinical data (e.g., patient
age, gender, primary illness, and associated comorbidities), risk
factors for candidemia (e.g., recent use of a CVC, recent use of
broad-spectrum antibiotics, recent hyperalimentation, neutrope-
nia, recent use of corticosteroids, prior major surgery, organ
transplantation, presence of diabetes mellitus, malignancy, receipt
of long-term dialysis, and HIV infection), and other variables
pertinent to candidemia (e.g., type of Candida species, duration of
hospitalization prior to the development of candidemia, duration
of candidemia, antifungal susceptibility testing, and therapy).
2.1. Laboratory diagnosis of candidemia and in vitro susceptibility
testing
For each patient, BD BACTEC aerobic and anaerobic blood
culture bottles (Becton Dickinson, Canada Inc., Mississauga,
Ontario, Canada) were each inoculated with 10 ml of blood and
transported to the laboratory within 1 h of collection. Bottles were
incubated in the BACTEC blood culture machine (Becton Dick-
inson) until ﬂagged positive by the machine. Gram stains were
performed for all positive cultures and these were subcultured on
blood, MacConkey, chocolate, and Sabouraud agar. Colonies on
Sabouraud agar were identiﬁed by Gram stain and the Candida
species were identiﬁed using API 20C AUX (bioMe´rieux, Paris,
France).
For disk diffusion sensitivity testing, the agar diffusion method
developed by Rosco (Rosco Diagnostica, Taastrup, Denmark) on
Mueller–Hinton agar with 2% glucose and 0.5 mg/ml methylene
blue was used as per the manufacturer’s recommendations.
Minimal inhibitory concentrations were determined using the
Etest (AB Biodisk, Solna, Sweden) as per the manufacturer’s
instructions.
2.2. Statistical analysis
Data were analyzed using IBM SPSS Statistics for Windows,
version 19.0 (IBM Corp., Armonk, NY, USA). The occurrence of
candidemia (C. albicans versus non-albicans Candida species) was
treated as a dependent variable in both univariate and multivariate
logistic regression analyses. Age, gender, use of a CVC, use of broad-
spectrum antibiotics, prior antifungal use, hyperalimentation,
neutropenia, use of corticosteroids, prior major surgery, diabetes
mellitus, malignancy, and long-term dialysis were treated asindependent categorical variables. Multiple associations were
evaluated in the multiple logistic regression model based on
backward stepwise selection. This procedure allowed the estima-
tion of the strength of the association between each independent
variable while taking into account the potential confounding
effects of the other independent variables. The adjusted measure of
association between risk factors and the independent variable was
expressed as the odds ratio (OR) with 95% conﬁdence interval (95%
CI). Adjusted or crude ORs with 95% CI that did not include 1.0 were
considered signiﬁcant. The Z-test was used to compare propor-
tions. Kaplan–Meier survival estimates were used to generate the
survival curves, and the median time to the event was used to
assess the differences between survival curves. A two-sided p-
value of <0.05 was considered statistically signiﬁcant.
3. Results
During the study period from January 2002 to December 2009, a
total of 258 BSI with Candida species were identiﬁed in 252
patients. More than one episode of candidemia occurred in three
female and three male patients. Only the ﬁrst episode of
candidemia was reported for patients with recurrent or subse-
quent episodes of infection. C. albicans represented 34.1% (n = 86)
and non-albicans Candida species represented 65.9% (n = 166) of
the total diagnosed candidemia. During the early years from 2002
to 2004, the number of non-albicans Candida species vs. C. albicans
cases was comparable (14 vs. 11; 10 vs. 14, and 22 vs. 19,
respectively) (p > 0.05). The gap was almost double in 2005 and
2006 (18 vs. 10 and 18 vs. 9, respectively), however the differences
were not statistically signiﬁcant (p > 0.05). The numbers of cases
of non-albicans Candida were much higher from 2007 to 2009 (30
vs. 5, 26 vs. 8, and 28 vs. 10, respectively) and the differences were
statistically signiﬁcant (p < 0.05) (Figure 1). The reported non-
albicans Candida species were Candida tropicalis (n = 39, 15.5%),
Candida parapsilosis (n = 30, 11.9%), Candida glabrata (n = 23, 9.1%),
Candida famata (n = 11, 4.4%), Candida krusei (n = 10, 4.0%), Candida
guilliermondii (n = 5, 2%), Candida lusitaniae (n = 2, 0.8%), and
Candida zeylanoides (n = 1, 0.4%). There were 45 (17.9%) cases of
non-albicans Candida species that were unspeciﬁed.
Demographic characteristics and risk factors associated with
the development of candidemia with C. albicans and non-albicans
Candida species are summarized in Table 1. There were 134 males
(53.2%) and 118 females (46.8%). Forty-nine patients (19.4%) were
less than 1 year old, 32 (12.7%) between 1 and 5 years old, 22 (8.7%)
between 6 and 14 years old, 83 (32.9%) between 15 and 59 years
old, and 66 (26.2%) were more than 60 years old (Table 1). In the
univariate analysis, candidemia with a non-albicans Candida
species compared to C. albicans was signiﬁcantly more likely to
develop among male than female patients (OR 1.86, 95% CI 1.10–
3.15); among patients 6–14 years old, 15–60 years old, and more
Table 1
Logistic regression analysis for risk factors associated with the development of candidemia with Candida albicans and non-albicans species
Risk factorsa Non-albicans Candida (n = 166) Candida albicans (n = 86) Univariate OR; 95% CI Adjusted OR; 95% CI
Gender:
Female (n = 118) 69 (58.5) 49 (41.5) 1 1
Male (n = 134) 97 (72.4) 37 (27.6) 1.86; 1.10–3.15b 1.67; 0.81–3.45
Age:
<1 year (n = 49) 23 (46.9) 26 (53.1) 1 1
1–5 years (n = 32) 19 (59.4) 13 (40.6) 1.65; 0.67–4.07 0.65; 0.18–2.29
6–14 years (n = 22) 18 (81.8) 4 (18.2) 5.09; 1.50–17.23b 0.52; 0.13–2.01
15–59 years (n = 83) 61 (73.5) 22 (26.5) 3.13; 1.49–6.59b 1.57; 0.28–8.86
60 years (n = 66) 45 (68.2) 21 (31.8) 2.42; 1.13–5.20b 1.44; 0.50–4.16
Admission to the ICU (n = 138) 92 (66.7) 46 (33.3) 1.08; 0.64–1.82 0.90; 0.40–2.03
Use of antibiotics (n = 158) 106 (67.1) 52 (32.9) 1.16; 0.68–1.97 1.24; 0.58–2.67
Prior antifungal therapy (n = 35) 23 (65.7) 12 (34.3) 0.99; 0.47–2.10 1.82; 0.65–5.07
Presence of a CVC (n = 204) 138 (67.6) 66 (32.4) 0.87; 0.48–1.59 2.07; 0.78–5.48
Malignancy (n = 113) 85 (75.2) 28 (24.8) 2.17; 1.26–3.75b 3.24; 1.25–8.41b
Hyperalimentation (n = 103) 64 (62.1) 39 (37.9) 0.76; 0.45–1.28 1.13; 0.47–2.75
Use of corticosteroids (n = 101) 64 (63.4) 37 (36.6) 0.83; 0.49–1.41 0.47; 0.22–1.03
Prior major surgery (n = 80) 51 (63.9) 29 (36.3) 0.87; 0.50–1.52 0.89; 0.41–1.97
Neutropenia (n = 76) 55 (72.4) 21 (27.6) 1.37; 0.76–2.48 0.88; 0.32–2.43
Diabetes mellitus (n = 73) 53 (72.6) 20 (27.4) 1.51; 0.83–2.74 1.65; 0.59–4.62
Long-term dialysis (n = 28) 24 (85.7) 4 (14.3) 3.30; 1.10–9.87b 1.85; 0.42–8.14
Organ transplantation (n = 5) 4 (80.0) 1 (20.0) 2.10; 0.23–19.07 -
OR, odds ratio; CI, conﬁdence interval; ICU, intensive care unit; CVC, central venous catheter.
a No HIV-positive cases were reported among the studied patients.
b Statistically signiﬁcant.
A.O. Al Thaqaﬁ et al. / International Journal of Infectious Diseases 21 (2014) 5–9 7than 60 years old compared to those less than 1 year old (OR 5.09,
95% CI 1.50–17.23; OR 3.13, 95% CI 1.49–6.59; and OR 2.42, 95% CI
1.13–5.20, respectively); among patients with malignancy (OR
2.17, 95% CI 1.26–3.75) and among patients with long-term
dialysis (OR 3.30, 95% CI 1.10–9.87). Other studied risk factors such
as admission to the ICU, use of broad-spectrum antibiotics, prior
use of azole antifungals, use of a CVC, hyperalimentation, use of
corticosteroids, prior major surgery, neutropenia, diabetes melli-
tus, and organ transplantation did not show any statistically
signiﬁcant differences for the development of non-albicans
Candida vs. C. albicans species candidemia in the univariate
regression analysis (Table 1). No cases of candidemia with
concomitant HIV were reported in the current study.
In the multivariate logistic regression analysis, only malignancy
was signiﬁcantly independently associated with the development
of non-albicans Candida species (OR 3.24, 95% CI 1.25–8.41). Other
variables entered into the equation were age, gender, ICU
admission, use of a CVC, prior use of broad-spectrum antibiotics,
prior use of azole antifungals, use of corticosteroids, use of
hyperalimentation, presence of neutropenia, diabetes mellitus,
long-term dialysis, and prior major surgery (Table 1).
Speciﬁcally, the incidences of C. albicans and C. glabrata were
higher among patients with solid compare to hematological
malignancies (34.5% vs. 26.2% and 27.6% vs. 4.9%, respectively). In
contrast, the incidences of the other non-albicans Candida species
were higher among patients with hematological than solid
malignancies: C. tropicalis (21.3% vs. 17.2%), C. parapsilosis (13.1%
vs. 10.3%), C. krusei (13.1% vs. 0.0%), C. famata (8.2% 0.0%), and other26.2
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Figure 2. Distribution of Candida albicans and non-albicans species according to the
type of tumor.unspeciﬁed non-albicans Candida species (13.1% vs. 10.3%). These
differences were not statistically signiﬁcant, except for C. glabrata
and C. krusei (p < 0.05) (Figure 2).
Fluconazole and amphotericin B were the initial antifungal
medications used in most cases (44.5% each), followed by
caspofungin (10.0%), amphotericin lipid complex (0.5%), and
voriconazole (0.5%). The use of sequential or combination
antifungal therapies was reported in 33.3% and 66.7% of C. albicans
and non-albicans Candida species patients, respectively. In vitro
antifungal susceptibility testing to ﬂuconazole was done for 187
cases (74.2%). Candifast, a colorimetric testing method, was used
until 2002 when it was replaced by the disk diffusion method,
which was then replaced by the Etest method in 2005. The average
percentage of Candida strains reported to be susceptible from 2002
to 2004 (when Candifast was used) was 27.3%. This percentage
increased to an average of 57.3% throughout the years from 2005 to
2009. The overall rate of in vitro susceptibility to ﬂuconazole was
38.5% for C. albicans, 50.0% for C. glabrata, 40.0% for C. tropicalis,
78.9% for C. parapsilosis, 37.5% for C. krusei, 57.1% for C. famata, and
53.1% for other Candida species. Amphotericin B in vitro
susceptibility testing was performed for 188 isolates (74.4%).
The overall rate of susceptibility to amphotericin B was 95.4% for C.
albicans, 90.0% for C. glabrata, 91.4% for C. tropicalis, 85.0% for C.
parapsilosis, 77.8% for C. krusei, 100.0% for C. famata, and 81.3% for
other Candida species (Figure 3).
Kaplan–Meier estimates of survival at the 12-month follow-up
after a positive blood culture, stratiﬁed by Candida species, are
reported in Figure 4. The overall, crude 12-month mortality rate38.5
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166 patients) for non-albicans Candida species. The median time to
death was signiﬁcantly longer in C. albicans (48.36 days) than non-
albicans Candida species cases (23.31 days) (p = 0.04).
4. Discussion
The current study included 252 patients with candidemia,
representing one of the largest cohorts of patients with candidemia
enrolled through an 8-year period (2002–2009) in Saudi Arabia.
Other large series of patients with candidemia in Saudi Arabia have
been reported by Al-Hedaithy13 and Al-Jasser and Elkhizzi17 (189
and 294 patients in 10 and 7 years, respectively). Meanwhile,
previous studies in similar hospitals in Saudi Arabia were carried
out in an earlier period and included relatively small numbers of
patients (range 31–98 candidemia cases).12,16
Non-albicans Candida species were the predominant group in
this study (65.9%). This is consistent with other reports of higher
rates for non-albicans Candida species, including that of Bukharie14
from Saudi Arabia, who observed a rate of 81%, which is the highest
reported rate of non-albicans Candida species infection. With the
exception of the study by Akbar and Tahawi,15 in which only 19%
frequency of non-albicans Candida species was reported, other
studies in Saudi Arabia have reported almost equal numbers of C.
albicans and non-albicans Candida species (range 47.0–
54.0%).12,13,16,17 For comparison, worldwide data of 134 715
consecutive clinical isolates of Candida species from 127 medical
centers in 39 countries (1997–2003) presented a clear trend
towards a decrease in C. albicans and an increase in C. tropicalis and
C. parapsilosis cases, and this is similar to the ﬁnding in our
center.18 In the current study, it was observed that the most
frequent non-albicans Candida species were C. tropicalis (15.5%) and
C. parapsilosis (11.9%), and not C. glabrata. C. glabrata has generally
been reported as the second most frequent Candida species from
the blood in the USA19 and UK,9 but has been isolated less
commonly in other regions.2 It should be emphasized that 45 non-
albicans Candida species cases were unidentiﬁed in the current
study (in the early years of the study, the microbiology laboratory
at KAMC did not routinely perform any further identiﬁcation of the
Candida isolates to the species level, a practice that was
importantly changed in 2006).
Published data have shown variable ﬁndings regarding the
predictors of candidemia due to C. albicans and non-albicansCandida species. For example, age 65 years, leukocytosis
(>15  109 cells/l), immunosuppressant therapy,20 and parenter-
al nutrition21 have been shown to be independently associated
with C. albicans infection. Conversely, old age, neutropenia, severe
immunosuppression or illness, parenteral nutrition,22 prior
antifungal therapy,21,24 use of a CVC,21,23 hematological malig-
nancy,22,24 prematurity,22 exposure to broad-spectrum antibio-
tics, use of corticosteroids,22 intra-abdominal surgery,21 recent
exposure to systemic antifungal therapy,21 female gender,23
admission to the ICU, and transplanted patients24 have more
commonly been identiﬁed among non-albicans candidemic
patients. These variable ﬁndings of studies from all over the
world are partly attributable to differences in host factors and
healthcare-associated practices, and obviously reﬂect the contin-
ual shift in the epidemiology of Candida species.11 Our ﬁndings are
partly consistent with those of the many reported studies in which
malignancy has been found to be independently associated with
non-albicans Candida species. With the exception of C. albicans and
C. glabrata, all the reported non-albicans Candida species in the
current study were more common in patients with hematological
than solid malignancies. This explains some of the predominance
of non-albicans Candida species in the current study, especially
since the number of patients with hematological malignancies
was double those with solid malignancies throughout the years
from 2002 to 2009.
Surprisingly, our results showed a low in vitro susceptibility rate
of Candida to ﬂuconazole (38.5% for C. albicans and 52.5% for non-
albicans Candida species). A similar in vitro ﬂuconazole susceptibility
pattern was reported by Osoba et al.16 in the same hospital (KAMC)
during the period 1998–2002 (47% and 17.7% for C. albicans and non-
albicans Candida species, respectively). It was observed that the use
of the Etest method in subsequent years, from 2005 to 2009, was
associated with improved ﬂuconazole susceptibility compared to
the Candifast method. The use of Candifast for the in vitro evaluation
of ﬂuconazole susceptibility among Candida spp in both clinical and
epidemiological studies is generally not preferred because of its
subjective criteria for reading the results and lack of standardization
in preparation of the inocula and/or the growth medium.25Although
the Etest offers the advantages of a practical application and
favorable rates of agreement with the reference methods, technical
errors may occur due to the trailing phenomenon,22 which is most
often encountered when there is incomplete growth inhibition and
is primarily observed with C. tropicalis and C. glabrata.26 Morace
et al.,22 in a multicentre comparative evaluation of six commercial
systems and the M27-A broth microdilution method (as a reference)
for ﬂuconazole susceptibility testing of Candida species, reported
that all six test methods (including Candifast, disk diffusion, and the
Etest) performed poorly (concordance range 24.8–68.4%) for C.
glabrata and C. krusei.22 They also reported that disk diffusion
showed poor correlation for non-C. albicans isolates. Moreover, the
current study reported three C. krusei cases susceptible to
ﬂuconazole (37.5%), which is not consistent with C. krusei resistance
patterns. All three cases were tested using the disk diffusion method.
Furthermore, our ﬁndings showed improved susceptibility to
ﬂuconazole in the four consecutive years following the introduction
of the Etest. However, a relative drop occurred again in 2008, in
concordance with the highest reported number of C. glabrata cases.
This inconsistency underscores the importance of reviewing
laboratory practices and validation of ﬂuconazole in vitro suscepti-
bility testing and appropriate training to minimize reading errors.26
Despite these issues, the present report suggests a major azole
resistance problem in our hospital; the cause is uncertain, but this
will likely encourage the more frequent use of echinocandins in the
treatment of invasive Candida infections.
The overall mortality in the current study was 50% for patients
with C. albicans and 57.8% for patients with non-albicans Candida
A.O. Al Thaqaﬁ et al. / International Journal of Infectious Diseases 21 (2014) 5–9 9species. These percentages are relatively higher than those
reported by Horn et al.11 (35%) and Diekema et al.8 (35.2%) in
the USA. However, they are similar to that reported by Kim et al.,27
who reported an overall mortality of 59%. There was no attempt to
provide an attributable mortality rate, which attempts to take
underlying disease outcomes into consideration. The current series
did reveal signiﬁcantly longer median survival times among
patients with C. albicans infections compared to non-albicans
Candida infections. This observation may be explained by the
underlying medical conditions, such as hematological and solid
malignancies.11,27 However, further analysis will be required to
investigate the attributable mortality risk factors accurately.
The important limitations of this study are its retrospective
nature and the laboratory investigations. Although some data were
collected prospectively, other variables (i.e., non-albicans Candida
subspecies) could not be explored because of missing data over a
long period before a review was performed. Furthermore, Candida
isolates were not stored, so repeat susceptibility testing could not
be carried out and drug resistance mechanisms could not be
investigated. We do not expect the unspeciﬁed non-albicans
Candida subspecies to have had much impact on the analysis, as
this group followed the same distribution pattern as the other
speciﬁed albicans and non-albicans species for both type of tumor
and antifungal susceptibility.
In conclusion, this study included a large cohort of patients
diagnosed with candidemia. Non-albicans Candida species were
predominant (65.9%). Malignancy was found to be independently
associated with the development of candidemia with these species.
Clearly, the high level of ﬂuconazole resistance is alarming and the
cause for this is not readily apparent from known epidemiologic
features. Furthermore, with the emergence of drug resistance and
the change in the epidemiologic patterns of candidemia, empiric
therapy for candidemia should be reviewed and possibly changed to
echinocandins.8 Based on this surveillance of fungemia, antimicro-
bial drug resistance trends, patient underlying medical conditions,
and high mortality, special emphasis should be placed on
investigating emerging environmental factors (extensive and
uncontrolled use of antifungal azoles in humans and agriculture),
and infection control measures and antimicrobial stewardship
should be revised to manage the emerging drug resistance, the
spread of yeasts, and the severity and outcome of candidemia.
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